Assessing cortical cerebral microinfarcts on iron-sensitive MRI in cerebral small vessel disease

Kim Wiegertjes¹, Kwok-Shing Chan², Annemieke ter Teltge¹, Benno Gesierich³, David G Norris²,4,5, Catharina JM Klijn¹, Marco Duering³,6, Anil M Tuladhar¹, José P Marques² and Frank-Erik de Leeuw¹

Abstract
Recent studies suggest that a subset of cortical microinfarcts may be identifiable on T2* but invisible on T1 and T2 follow-up images. We aimed to investigate whether cortical microinfarcts are associated with iron accumulation after the acute stage. The RUN DMC – InTENse study is a serial MRI study including individuals with cerebral small vessel disease (SVD). 54 Participants underwent 10 monthly 3 T MRIs, including diffusion-weighted imaging, quantitative R1 (=1/T1), R2 (=1/T2), and R2* (=1/T2*) mapping, from which MRI parameters within areas corresponding to microinfarcts and control region of interests (ROIs) were retrieved within 16 participants. Finally, we compared pre- and post-lesional values with repeated measures ANOVA and post-hoc paired t-tests using the mean difference between lesion and control ROI values. We observed 21 acute cortical microinfarcts in 7 of the 54 participants (median age 69 years [IQR 66–74], 63% male). R2* maps demonstrated an increase in R2* values at the moment of the last available follow-up MRI (median [IQR], 5 [5–14] weeks after infarction) relative to prelesional values (p = .08), indicative of iron accumulation. Our data suggest that cortical microinfarcts are associated with increased R2* values, indicative of iron accumulation, possibly due to microhemorrhages, neuroinflammation or neurodegeneration, awaiting histopathological verification.

Keywords
Acute ischemia, cerebrovascular disease, cortical microinfarcts, magnetic resonance imaging, small vessel disease

Received 5 February 2021; Revised 23 June 2021; Accepted 28 June 2021

Introduction
Cortical microinfarcts are frequently encountered on neuropathological examination of brains of elderly individuals, especially in those with cerebrovascular disease or dementia.¹,² Nonetheless, only a small proportion (<1%) of the total microinfarct burden can be detected with MRI, clearly limiting our understanding of the causes and consequences of microinfarcts.³

In the RUN DMC – InTENse study, a monthly serial imaging study, we detected acute cortical microinfarcts (A-CMI) in 13% of the participants.⁴ However, none of the A-CMI turned into a chronically visible lesion on follow-up MRI.⁵,⁶ This mismatch between detection of A-CMI and chronic microinfarcts (C-CMI) may be explained by the fact that C-CMI have currently been defined to be isointense on
iron-sensitive MRI sequences. A recent in vivo 3T MRI study, demonstrated that 56% of the detected A-CMI demonstrated visible signal alterations on susceptibility-weighted imaging (SWI) after 1 to 3 years, whereas signal alterations on follow-up T2-weighted imaging were found in only 29% of the A-CMI.

However, SWI dichotomizes tissue into abnormal and normal tissue and tends to extend regions of high susceptibility (blooming artefact) which appear as dark voids that are not reliable for quantification of the degree of iron accumulation. This limitation is overcome by using R2* mapping, which is a quantitative relaxometry metric whose changes can be linearly related to changes in local brain concentration (an increase in R2* is associated with a given increase in concentration of iron), thereby providing a detailed evaluation of the underlying tissue alterations at the voxel level. Therefore, the aim of this study was to investigate whether initial acute cortical microinfarcts are associated with signal alterations on R2* mapping indicative of iron accumulation after the acute stage.

**Materials and methods**

**Study design and subjects**

Participants were included from the RUN DMC – InTENse (Radboud University Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort – Investigating The origin and Evolution of cerebral small vessel disease) study. Details of the study protocol and MRI processing have been described previously. Briefly, we selected 54 participants with progressive sporadic SVD (median [IQR] 69 years [66–74], 63% male) from the ongoing RUN DMC study. Because previous WMH progression is the most important determinant of future WMH progression, individuals were invited by volume of WMH progression on MRI scans between 2006 and 2015, while meticulously excluding those individuals with other causes of cerebral ischemia. Participants with intracranial haemorrhage on MRI (except microbleeds), dementia, Parkinson’s diseases, life expectancy <1 year, or 3 T MRI contraindication were also excluded. Participants underwent a pre-screening visit to assess study eligibility, cardiovascular risk factors and cognition and 10 monthly MRI scans. Cardiovascular risk factors were defined as previously described. Data were collected between March 2016 and November 2017.

**Standard protocol approvals, registrations, and patient consents**

The study was approved by the medical ethics committee region Arnhem-Nijmegen. All participants provided written informed consent. The guidelines according to the Declaration of Helsinki were followed.

**MRI protocol and processing**

Participants underwent monthly MRI scanning in a 3 T scanner (MAGNETOM Prisma, Siemens Healthineers, Erlangen, Germany) with a 32-channel head coil. The MRI protocol was specified in detail previously, and included the following sequences relevant to the current study: 3 D T1 mapping (MP2RAGE) for R1 mapping (1/T1) with 0.85 mm isotropic voxels, multiple spin echo T2-weighted imaging for R2 mapping (1/T2) and reconstructed voxel size 0.36 × 0.36 × 3.3 mm; 3 D fluid-attenuated inversion recovery (FLAIR) with 0.85 mm isotropic voxels; multi-shell DWI including 90 diffusion-weighted directions (30 = b = 1000, and 60 × b = 3000 s/mm2) and 10 non-diffusion-weighted scans (b = 0) with 1.7 mm isotropic voxels and multiband acceleration factor 3, and one b = 0 image with imaging parameters equal to the previous DWI but with reversed phase-encoding direction for susceptibility-induced distortion correction. Diffusion data were processed as described previously. Diffusion-weighted trace images were generated based on the arithmetic mean across all diffusion directions within one shell, and mean diffusivity (MD) and fractional anisotropy (FA) maps were calculated on the inner shell using dtifit in FSL; 3 D multiecho gradient echo sequence (GRE) providing magnitude and phase images (6 echoes; ΔTE = 4.92 ms) for susceptibility weighted images and R2* mapping (1/T2*) with 0.8 × 0.8 × 2.0 mm voxels. To create the SWI images, phase images were high-pass filtered using a 2 D hammering filter with a 12 × 12 kernel across all image slices and all echoes. The high-pass filtered phase images were subsequently self-multiplied four times (i.e., m = 4), before combining to the magnitude data as described previously. The magnitude SWI images were then subsequently averaged across all echoes to produce the final SWI image. R2* maps were derived from the multi-echo magnitude GRE data, using the closed-form solution based on the trapezoidal rule to approximate the integration of the magnitude decay, as described previously, implemented in a custom-written tool (https://github.com/kschan0214/r2starmapping) in Matlab.

**Acute cortical microinfarcts**

A-CMI were defined as <5 mm hyperintense lesions on DWI restricted to the cerebral cortex, with a
corresponding hypo- or isointense signal on the mean diffusivity (MD) map. All monthly DWI scans were assessed for A-CMI and manually segmented, with high spatial overlap between segmentations of the two raters (interquartile range [IQR] = 0.8–1.0). Afterwards, the A-CMI were visually inspected on T1/FLAIR scans of the same visit as A-CMI onset and the last follow-up visit as described previously, and on SWI/R2* scans of these same visits.

**Chronic cortical microinfarcts**

C-CMI were defined as lesions <5 mm in diameter restricted to the cerebral cortex, according to previously published criteria. Two trained raters screened all baseline and last follow-up scans, masked to clinical information. Final consensus was reached involving more raters (M.D.; S.J. van Veluw, PhD, Massachusetts General Hospital), after which true C-CMI were visually inspected on SWI/R2* scans of the first visit.

**Other MRI markers of SVD**

As described previously, conventional MRI markers of SVD, including white matter hyperintensities (WMH), lacunes, and cerebral microbleeds (CMB) were assessed according to the universally standardized STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) criteria. WMH volumes were reported as the proportion of total white matter volume.

**Imaging analysis**

To assess lesion evolution, skull-stripped images of different modalities (T1, T2, GRE, DWI) were registered to the DWI image of the first visit using the FMRIB Software Library (FSL) Linear Image Registration Tool (FLIRT). First, images were registered to the MP2RAGE image of the same visit. This included registration between MP2RAGE and GRE images, and between MP2RAGE and DWI images. Second, registration between the different visits was performed by registering all MP2RAGE images to the one acquired in the first visit. All transformation matrices derived from the first and second steps were concatenated and applied to coregister images of the other modalities and lesion masks to the DWI image of the first visit. To minimize the effect of interscan variability, we created a control region of interest (ROI) outside the lesion by dilating the A-CMI mask one voxel in all directions followed by subtraction of the original lesion ROI. As R2* maps were subject to motion artifacts affecting different locations in the brain, which were not systematic across time points, a control ROI in the contralateral hemisphere would introduce biases in our measurements. Nevertheless, when using a control ROI in a proximal region both lesion and control ROIs should have similar biases, which could be eliminated when computing the mean difference between the two ROIs.

**Statistical analysis**

Statistical analyses were performed in R (version 3.6.2; https://www.R-project.org) and α was set at .05, two-tailed. Demographics, cardiovascular risk factors and baseline SVD characteristics of participants with any (chronic or acute) CMIs were compared to those without using the Mann-Whiney test for continuous and chi-square test for categorical independent variables (or Fisher’s exact test where appropriate).

We calculated the mean of the different MRI parameters (DWI trace, MD, FA, R1, R2, and R2* values) within the lesion and control ROI at each time point. To mitigate partial volume effects from cerebrospinal fluid (CSF) and white matter, only voxels with R2* values ranging from 5 s⁻¹ to 30 s⁻¹ were accepted in the final analyses to avoid inclusion of voxels dominated by CSF (very low R2* values) and white matter (typically ~30 s⁻¹). While the typical cortical grey matter R2* is around 15 s⁻¹ and the mean R2* of A-CMI was 19 s⁻¹ across all MRI sessions in this study. The difference between the mean signal in the lesion and control ROI was used in the analysis, followed by the subtraction of the mean difference of all timepoints before lesion onset to ensure any differences between control and lesion ROIs due to residual partial volume was further minimized. To be able to study the dynamic evolution of the extracted parameters, they were temporally realigned in respect to the onset time, the visit in which the A-CMI initially appeared on the MRI (designated as “MRI 0”). We classified MRI parameters as follows: (1) MRI before the onset of a new lesion (“pre-lesional”); (2) MRI at which a new lesion is first identified (“lesional”); (3) last available follow-up MRI (“post-lesional”). We used a one-way repeated measures ANOVA and post-hoc 2-tailed paired-samples t tests to compare lesion values from the three time points (pre-lesional, lesional, post-lesional).

**Data availability**

Data requests can be sent to the corresponding author (FrankErik.deLeeuw@radboudumc.nl).

**Results**

Of the 54 included subjects (median age 69 years [IQR 66-74], 63% male) 52 underwent follow-up MRI
In total, 22 of the 54 individuals had (acute or chronic) CMIs during the study period. Individuals with any CMIs were significantly older compared to those without (median [IQR] 73 [67–80] vs 68 [65–70] years, \( p = .014 \), Table 1). Other baseline characteristics were similar (all \( p > .05 \)).

Between March 2016 and November 2017, we observed 21 A-CMI in 7 of the 54 participants (13% [0.06–0.24]). Of these, 20 (95%) were visible on FLAIR and T1 images at the moment of appearance, 9 (43%) were hypointense on R2* maps in the acute stage (Figure 1). Of these 9 A-CMI, two were hyperintense and seven were isointense on SWI images. The remaining 12 A-CMI (57%) were isointense on both R2* and SWI. For 20 of the 21 A-CMI (95%), one or more follow-up MRI scans were available. Whereas none of the A-CMI was visible on the FLAIR and T1 images of the last available follow-up MRI, 4/20 (20%) A-CMI demonstrated a hyperintense signal on R2* maps and a hypointense signal on SWI images, indicative of iron accumulation (Figure 1). These 4 A-CMI all demonstrated a hypointense R2* signal at the moment of appearance. None of the other 16 A-CMI were visible on follow-up MRI (R2* or SWI images).

For, 15 of the 21 (71%) A-CMI time series data analysis could be performed. We excluded four A-CMI because they appeared on the first or last available follow-up MRI and therefore either pre- or post-

---

**Table 1. Group characteristics.**

|                      | No cortical microinfarct (n = 32) | Any cortical microinfarct (n = 22) | \( p \) |
|----------------------|-----------------------------------|-----------------------------------|--------|
| **Demographic variables** |                                   |                                   |        |
| Age (years)          | 68 (65–70)                        | 73 (67–80)                        | .014   |
| Men                  | 17 (53%)                          | 17 (77%)                          | .071   |
| Level of education   | 5 (5–6)                           | 5 (5–6)                           | .628   |
| **Cardiovascular risk factors** |                                 |                                   |        |
| Hypertension         | 24 (75%)                          | 21 (96%)                          | .067   |
| Diabetes             | 4 (13%)                           | 2 (9%)                            | 1.00   |
| Hypercholesterolemia | 16 (50%)                          | 11 (50%)                          | 1.00   |
| BMI (kg/m²)          | 26 (4)                            | 26 (4)                            | .881   |
| Smoking (ever)       | 22 (69%)                          | 22 (69%)                          | .753   |
| **Baseline MRI characteristics** |                               |                                   |        |
| WMH volume\(^a\)     | 0.80% (0.51–1.99)                 | 1.54% (0.86–3.05)                 | .138   |
| Lacunes, presence    | 5 (16%)                           | 7 (32%)                           | .194   |
| Microbleeds, presence| 14 (44%)                          | 11 (50%)                          | .651   |

\(^a\)WMH volume was calculated as (WMH volume/WM volume) × 100.

---

**Figure 1.** Examples of R2* signal change at the location of acute cortical microinfarcts. Acute cortical microinfarcts detected on diffusion-weighted imaging (DWI) trace images (shown here \( b = 3000 \)), accompanied by a hypointense signal on R2* in the acute stage in both panel A and in panel B. On the last available follow-up MRI, the microinfarct in panel A is characterized by an increased signal on R2* and a decreased signal on SWI, indicative of iron accumulation, whereas in panel B no visible signal alterations were observed on either R2* or SWI images at the location of the microinfarct (B).
lesional values were unavailable, and two because they were located too close to the pial surface to exclude partial volume effects. There was a statistically significant main effect of time on DWI trace values ($p < 0.001$). At the moment of occurrence, DWI trace values were significantly increased compared to pre-lesional values five weeks earlier (median [IQR], 5 [4–5]) and post-lesional values (both $p < 0.001$; Figure 2) five weeks later (median, [IQR], 5 [5–14]). However, post-lesional values were similar to pre-lesional values. Moreover, we found a significant effect of time on MD values ($p < 0.001$). Specifically, MD was significantly lower compared to its pre-lesional value at the time of lesion appearance ($p = 0.002$). Post-lesional MD values were significantly higher than lesional values ($p < 0.001$), whereas values of the last available follow-up MRI were not statistically different from pre-lesional values. There were no significant changes in FA values over time at the location of the lesion. However, there was a statistically significant main effect of time on R1 values ($p < 0.001$). At the time of the lesion detection, R1 values were significantly lower than pre-lesional ($p < 0.001$) or post-lesional values ($p = 0.002$). At the last available follow-up MRI, values returned to pre-lesional R1 values. R2 values demonstrated a significant change over time ($p = 0.036$). At the time of lesion detection, R2 demonstrated a significant decrease compared to pre-lesional values ($p = 0.019$), whereas lesional values were similar to values of the last available follow-up MRI. Moreover, post-lesional did not differ significantly from pre-lesional values. Lastly, R2* values demonstrated a significant change over time ($p = 0.017$). A negative trend was observed for R2* values, with R2* values decreasing from pre-lesional levels at the moment of A-CMI appearance ($p = 0.066$). Compared to lesion values, R2* values significantly increased at the moment of post-lesional

Figure 2. Longitudinal changes in MRI parameters at the location of acute cortical microinfections. Different MRI parameters are shown: (A) diffusion-weighted imaging trace (DWI), (B) mean diffusivity (MD), (C) fractional anisotropy (FA), (D) longitudinal relaxation rate (R1), (E) transverse relaxation rate (R2), and (F) Apparent transverse relaxation rate (R2*). Plotted transparent lines correspond to individual lesions and indicate the normalized mean difference between the lesion and control ROI at each time point. The mean and the standard deviation (SD) are highlighted as solid lesions and shaded regions.
follow-up MRI \((p = .015)\). Thereafter, R2* values showed a non-significant increase to higher than pre-lesional levels at the moment of the post-lesional follow-up MRI \((p = .077)\). Furthermore, these observations were unchanged when choosing other control regions further away from the cortical infarct.

To investigate the prevalence of iron-positive microinfarcts in the chronic stage, we assessed the R2* signal change in the 81 C-CMI detected previously in 19 of the 53 participants (35\% [95\% CI 0.24–0.49]) of the RUN DMC – InTENse study population. Of these, 17 (21\%) were hyperintense on R2* maps and hypointense on SWI images on the baseline MRI (Figure 3), consistent with the accumulation of iron. Whereas, 38 of the 81 (47\%) C-CMI were hypointense on baseline R2* maps demonstrating CSF-like properties (35 showed cavitation on FLAIR images). These 38 C-CMI were all isointense on SWI baseline images. The remaining 26 C-CMI were isointense on both R2* maps and SWI images of the first visit.

**Discussion**

We found an increase in R2* at the location of A-CMI, suggestive of iron accumulation, whereas the changes found in diffusion, R1 and R2 parameters at the moment of appearance of A-CMI disappeared from follow-up MRI. These results suggest that we should reconsider the formerly established criteria for the rating of microinfarcts, as C-CMI have currently been defined to be isointense on iron-sensitive MRI scans.

Traditionally, MR lesions visible on GRE are believed to represent accumulation of iron consistent with hemosiderin-laden macrophages in perivascular tissue, corresponding to vascular leakage of blood cells. Inherently, this suggests that the observed iron accumulation as picked up by R2* at the site of A-CMI could be the result of hemorrhagic transformation. This is in line with recent *in vivo* studies that described hemorrhagic transformation of subcortical

**Figure 3.** Example of R2* signal change at the location of a chronic cortical microinfarct.

Example of a chronic cortical microinfarct demonstrating iron accumulation, characterized by a hypointense signal on T1, a hyperintense signal on T2, a hypointense signal on susceptibility-weighted imaging (SWI), and a hyperintense signal on R2*.
DWI+ lesions into a MRI-detectable microbleed,\textsuperscript{4,28} and with the small number of post-mortem MRI studies that have demonstrated a shared underlying histopathology of cerebral microbleeds and microinfarcts.\textsuperscript{29,30} Furthermore, a previous neuropathological study demonstrated different types of C-CMI using 7 T post-mortem MRI, including C-CMI with or without cavitation, and C-CMI with or without hemorrhagic components.\textsuperscript{30}

However, the more subtle changes in iron (as picked up by the quantitative R2*) could have more potential underlying causes. A combined \textit{in vivo} histopathology-MRI study found several pathological changes at the core of C-CMI, including extracellular accumulation of lipofuscin and depletion of neurons, and activated macrophages and astroglia with a varying degree of iron accumulation.\textsuperscript{31} These changes were not found at the location of A-CMI. First, the extracellular accumulation of lipofuscin could be one possible source of iron. Lipofuscin aggregates as a result of neuronal cell death, and could therefore signify the beginning of tissue necrosis, a process which could ultimately result in C-CMI with cavitation.\textsuperscript{32,33} Another explanation could be the activation of macrophages associated with neuroinflammation,\textsuperscript{34} characterized by the presence of microglial cells which have been described to have a high content of ferritin.

The changes found in R1 and R2 parameters at the moment of A-CMI appearance showed normalization already on the subsequent follow-up MRI, consistent with our previous findings.\textsuperscript{6} However, because we were not able to investigate the disappearing A-CMI on brain pathology, it remains unclear whether this indicates tissue salvation or whether tissue damage persists that is not visible on \textit{in vivo} 3 T MRI. Prior research on subcortical DWI lesions has demonstrated that of the DWI+ lesions that cavitated on follow-up MRI, in general only a small part of the initial DWI+ lesion showed cavitation, whereas the largest part of the DWI+ lesion had no signal abnormality on follow-up MRI.\textsuperscript{35} As CMI are typically very small in size (between 0.05 and 5 mm in diameter), the proportion of the tissue that remains visible on follow-up MRI might be too small to be detected with \textit{in vivo} 3 T MRI. Although we are unsure whether these findings on subcortical DWI+ lesions can be translated to the cortex, several MRI studies demonstrated that especially small cortical infarcts seem to disappear during follow-up.\textsuperscript{4,36,37}

Our findings accentuate the notion that cortical microinfarcts affect brain structure beyond the acute period. Due to the poor spatial and temporal resolution of \textit{in vivo} MRI, a single A-CMI large enough to be detected on DWI scans, although having a limited effect by itself, may be indicative of a yearly incidence of hundreds of new microinfarcts,\textsuperscript{38} which all together may have a substantial effect on the brain. Furthermore, it has recently been suggested that microinfarcts could be associated with focal cortical atrophy,\textsuperscript{3,37,39} in which accumulation of iron could be a key mechanism. Future \textit{in vivo} combined histopathology-MRI studies should investigate the causes and consequences of iron accumulation in the evolution of A-CMI into C-CMI, and its effect on the surrounding brain structure.

This study has several strengths and limitations. This is, to the best of our knowledge the first prospective \textit{in vivo} study which investigated the R2*-based quantification of iron deposition, in the evolution of A-CMI to C-CMI. Major strengths include its monthly imaging and the use of quantitative high-resolution MRI data. Furthermore, our participants represent a well-defined SVD sample. However, due to the low sample size and small number of A-CMI, this study might have been underpowered to find associations with small or medium effect sizes. Therefore, a future study with a larger sample size could be beneficial to investigate lesion development using quantitative MRI.

Second, we cannot exclude errors due to registration processes or partial volume effects, as microinfarcts are by definition located on the cortical surface of the brain, thus very close to tissue boundaries. However, we assume these errors to be small as all images were thoroughly checked using visual inspection. Third, the spatial resolution of the R2* data might have limited our analysis. Especially, small DWI+ lesions, significantly below the 2.0 mm slice thickness, might have gone undetected because of partial volume effects, and consequently R2* changes at visual assessment might have been missed. Future studies should acquire R2* data with higher through-slice resolution to limit the intra-voxel partial volume effect and with longer echo times to ensure higher SNR of the R2* maps. Fourth, we were not able to pathologically confirm that the observed increases in R2* indeed represent iron accumulation. While previous studies using a combined MRI-histopathology approach demonstrated a high correlation between R2* values and iron concentration in grey matter,\textsuperscript{22,40} other local background sources confound the measurement of tissue iron content as they also relate to the R2* signal, such as cell density or other trace elements.\textsuperscript{9} Furthermore, the observed changes in magnetic susceptibility could be due to other causes than iron depositions. For instance, deoxygenated hemoglobin trapped in small blood clots or in venous blood could also result in fast R2* changes. Nevertheless, the presence of blood clots in blood vessels of otherwise healthy and asymptomatic individuals seems rather unlikely. Moreover, both an increase in myelination and an increase of iron
concentration could result in an increased R2\* signal. As a result, if iron deposition occurs concurrently to demyelination, R2\* changes would be smaller than expected and underestimate the increase of iron deposition. However, since we focussed on cortical grey matter regions in this study, a region of low myelin concentration (when compared to the white matter), the contribution of myelin to the R2\* signal is less significant.

These findings indicate that some cortical microinfarcts detected in vivo are characterized by iron accumulation, possibly due to microhemorrhages, neuroinflammation, or neurodegeneration, awaiting further histopathological verification. This may call for inclusion of iron-sensitive MRI scans in the MRI requirements for the detection of CMI. Future in vivo combined-histopathology-MRI studies should further investigate the causes and consequences of iron accumulation in the evolution of A-CMI into C-CMI.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: BG and MDu were supported by the German Research Foundation (DFG, DU1626/1-1). MD received funding from the Radboud Excellence Initiative (18 U.018,651). AMT was supported by the Dutch Heart Foundation (grant 2016 T044). AMT is supported by the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation (CVON 2018-28 & 2012-06 Heart Brain Connection), Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences. CJMK was supported by a clinical established investigator grant of the Dutch Heart Foundation (grant no. 2012 T077), and by an Aspasia grant from The Netherlands Organization for Health Research and Development (ZonMw grant no. 0.15.008.048). JPM and KC were supported by The Netherlands Organization for Scientific Research (NWO grant FOM-N-31/16PR1056). FEdL was supported by a clinical established investigator grant of the Dutch Heart Foundation (grant 2014 T060), and by a VIDI innovational grant from The Netherlands Organization for Health Research and Development, ZonMw (grant 016126351).

**Acknowledgements**

We would like to thank Brendon Sri Baskaran, Susanne J. van Veluw and Doeschka A. Ferro for their help with the assessment of cortical microinfarcts and their support with the customized tool within MeVisLab. The authors would like to thank Siemens Healthineers for providing the sequence for accelerated T2 mapping based on WIP899b.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Authors’ contributions**

KW participated in data acquisition, performed statistical analysis, data interpretation, and drafting and revising of the manuscript. KSC performed statistical analysis, interpreted the data and revised the manuscript for intellectual content. CJMK interpreted the data and revised the manuscript for intellectual content. AtT and MD contributed to study concept and design, and revised the manuscript for intellectual content. BG and MDu participated in data acquisition and revised the manuscript. AMT and JPM contributed to data interpretation, performed statistical analysis, and revised the manuscript for intellectual content. FEdL contributed to study concept and design, data interpretation, obtained funding, and revised the manuscript for intellectual content. Data request can be sent to the corresponding author (FrankErk.deLeeuw@radboudumc.nl).

**References**

1. Brundel M, de Bresser J, van Dillen JJ, et al. Cerebral microinfarcts: a systematic review of neuropathological studies. *J Cereb Blood Flow Metab* 2012; 32: 425–436.
2. Smith EE, Schneider JA, Wardlaw JM, et al. Cerebral microinfarcts: the invisible lesions. *Lancet Neurol* 2012; 11: 272–282.
3. van Veluw SJ, Shih AY, Smith EE, et al. Detection, risk factors, and functional consequences of cerebral microinfarcts. *Lancet Neurol* 2017; 16: 730–740.
4. Telgte A, Wieghertjes K, Gesierich B, et al. Contribution of acute infarcts to cerebral small vessel disease progression. *Ann Neurol* 2019; 86: 582–592.
5. Telgte A, Wieghertjes K, Tuladhar AM, et al. Investigating the origin and evolution of cerebral small vessel disease: the RUN DMC – InTENse study. *Eur Stroke J* 2018; 3: 369–378.
6. Telgte A, Wieghertjes K, Gesierich B, et al. Temporal dynamics of cortical microinfarcts in cerebral small vessel disease. *JAMA Neurology* 2020; 77: 643–647.
7. Miyata M, Kakeda S, Yoneda T, et al. Signal change of acute cortical and juxtacortical microinfarction on follow-up MRI. *AJNR Am J Neuroradiol* 2018; 39: 834–840.
8. Liu C, Li W, Tong KA, et al. Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. *J Magn Reson Imaging* 2015; 42: 23–41.
9. Brass SD, Chen NK, Mulkern RV, et al. Magnetic resonance imaging of iron deposition in neurological disorders. *Top Magn Reson Imaging* 2006; 17: 31–40.
10. van Norden AG, de Laat KF, Gons RA, et al. Causes and consequences of cerebral small vessel disease. The RUN DMC study: a prospective cohort study. Study rationale and protocol. *BMC Neurol* 2011; 11: 29.
11. Adam G, Ferrer M, Petsoura S, et al. Magnetic resonance imaging of arterial stroke mimics: a pictorial review. *Insights Imaging* 2018; 9: 815–831.
12. Marques JP, Kober T, Krueger G, et al. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. *Neuroimage* 2010; 49: 1271–1281.
13. Hilbert T, Sumpf TJ, Weiland E, et al. Accelerated T2 mapping combining parallel MRI and model-based reconstruction: GRAPPATINI. *J Magn Reson Imaging* 2018; 48: 359–368.

14. Xu JQ, Moeller S, Auerbach EJ, et al. Evaluation of slice accelerations using multiband echo planar imaging at 3 T. *Neuroimage* 2013; 83: 991–1001.

15. Andersson JLR, Skare S and Ashburner J. How to correct susceptibility distortions in spin-echo planar images: application to diffusion tensor imaging. *Neuroimage* 2003; 20: 870–888.

16. Soares JM, Marques P, Alves V, et al. A hitchhiker’s guide to diffusion tensor imaging. *Front Neurosci* 2013; 7: 31.

17. Haacke EM, Mittal S, Wu Z, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. *AJNR Am J Neuroradiol* 2009; 30: 19–30.

18. Khabipova D, Wiaux Y, Gruetter R, et al. A modulated closed form solution for quantitative susceptibility mapping – a thorough evaluation and comparison to iterative methods based on edge prior knowledge. *Neuroimage* 2015; 107: 163–174.

19. van Veluw SJ, Hilal S, Kuifjf HJ, et al. Cortical microinfarcts on 3T MRI: clinical correlates in memory-clinic patients. *Alzheimers Dement* 2015; 11: 1500–1509.

20. Wardlaw JM, Smith EE, Biessels GJ, et al.; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research and clinical methods for recognition and study of cortical microinfarcts in thick sections. *Eur J Histochem* 2018; 62.

21. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. *Neuroimage* 2004; 23 Suppl 1: S208–219.

22. Langkammer C, Krebs N, Goessler W, et al. Quantitative MR imaging of brain iron: a postmortem validation study. *Radiology* 2010; 257: 455–462.

23. Weiskopf N, Suckling J, Williams G, et al. Quantitative multi-parameter mapping of R1, PD(*), MT, and R2(*) at 3T: a multi-center validation. *Front Neurosci* 2013; 7: 95.

24. Shoamanesh A, Kwok CS and Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging. *Cerebrovasc Dis* 2011; 32: 528–534.

25. Fazekas F, Kleinitz R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. *AJNR Am J Neuroradiol* 1999; 20: 637–642.

26. Dichgans M, HoltmannspäTier M, Herzog J, et al. Cerebral microbleeds in CADASIL – a gradient-echo magnetic resonance imaging and autopsy study. *Stroke* 2002; 33: 67–71.

27. Tatsumi S, Shinohara M and Yamamoto T. Direct comparison of histology of microbleeds with postmortem MR images: a case report. *Cerebrovasc Dis* 2008; 26: 142–146.

28. van Veluw SJ, Lauer A, Charidimou A, et al. Evolution of DWI lesions in cerebral amyloid angiopathy: evidence for ischemia. *Neurology* 2017; 89: 2136–2142.

29. van Veluw SJ, Biessels GJ, Klijn CJ, et al. Heterogeneous histopathology of cortical microbleeds in cerebral amyloid angiopathy. *Neurology* 2016; 86: 867–871.

30. van Veluw SJ, Zwanenburg JJ, Rozemuller AJ, et al. The spectrum of MR detectable cortical microinfarcts: a classification study with 7-tesla postmortem MRI and histopathology. *J Cereb Blood Flow Metab* 2015; 35: 676–683.

31. Yilmazer-Hanke D, Mayer T, Muller HP, et al. Histological correlates of postmortem ultra-high-resolution single-section MRI in cortical cerebral microinfarcts. *Acta Neuropathol Com* 2020; 8: 33.

32. Rathnasamy G, Ling EA and Kaur C. Consequences of iron accumulation in microglia and its implications in neuropathological conditions. *CNS Neurol Disord Drug Targets* 2013; 12: 785–798.

33. Braak H, Feldengut S, Kassubek J, et al. Two histological methods for recognition and study of cortical microinfarcts in thick sections. *Eur J Histochem* 2018; 62.

34. Haacke EM, Cheng NYC, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. *Magn Reson Imaging* 2005; 23: 1–25.

35. Duering M, Adam R, Wollenweber FA, et al. Within-lesion heterogeneity of subcortical DWI lesion evolution, and stroke outcome: a voxel-based analysis. *J Cereb Blood Flow Metab* 2020; 40: 1482–1491.

36. Havsteen I, Ovesen C, Willer L, et al. Small cortical grey matter lesions show no persistent infarction in transient ischaemic attack? A prospective cohort study. *Bmj Open* 2018; 8: e018160.

37. Summers PM, Hartmann DA, Hui ES, et al. Functional deficits induced by cortical microinfarcts. *J Cereb Blood Flow Metab* 2017; 37: 3599–3614.

38. Auriel E, Westover MB, Bianchi MT, et al. Estimating total cerebral microinfarct burden from diffusion-weighted imaging. *Stroke* 2015; 46: 2129–2135.

39. Coban H, Tung S, Yoo B, et al. Molecular disorganization of axons adjacent to human cortical microinfarcts. *Front Neurol* 2017; 8: 405.

40. Li TQ, Yao B, van Gelderen P, et al. Characterization of T(2)* heterogeneity in human brain white matter. *Magn Reson Med* 2009; 62: 1652–1657.